UTAH MEDICAL PRODUCTS INC
Utah Medical Products makes medical devices for hospitals, outpatient clinics and physician offices, with products used especially in neonatal intensive care, labor and delivery, and women’s health. Its products include fetal monitoring accessories, obstetric tools and vacuum-assisted delivery systems; neonatal catheters, feeding and drainage devices, and blood pressure monitoring systems; and gynecology, urology and electrosurgery products. Brands include INTRAN PLUS, Disposa-Hood, Gesco, LETZ and the Filshie Clip System. The company sells devices directly to medical facilities and through distributors and other medical device companies. It also manufactures components and finished devices on a subcontract basis. In the U.S., it sells directly to clinical end users or stocking distributors. Outside the U.S., it sells directly in Canada, the UK, France, Ireland, Australia and New Zealand, and through distributors in other countries. Utah Medical Products is headquartered in Midvale, Utah, and has manufacturing operations in Ireland.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Utah Medical Products reported 3Q 2026 revenue of $8.62M, down 12.1% YoY, and net income of $2.79M, up 5.9% YoY. The decline was attributed to lower sales to former major customers and declining Filshie sales, while earnings were supported by lower expenses and a lower tax rate. Management expects full-year 2026 sales to decline 7%-8% from 2025, with EPS close to $3.60 per share.
UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Utah Medical Products, Inc. Increases Quarterly Dividend Contact: Brian Koopman November 3, 2026 (801) 566-1200 Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors has approved a quarterly cash dividend of thirty-on
Utah Medical Products (UTMD) raised its quarterly dividend by 1.6% to $0.315 per share. The payment is scheduled for January 5, 2027, to shareholders of record on December 17, 2026. The company develops specialty medical devices for women and babies.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning UTMD (UTAH MEDICAL PRODUCTS INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent UTMD coverage spans corporate actions, earnings and insider activity.
In the last 30 days, UTMD insiders filed 1 SEC Form 4 transaction — 1 purchase ($67K) and no sales. The most active reporter was CORNWELL KEVIN L, Chairman, CEO, with 1 filing.
Revenue decline may pressure the stock, while EPS beat could provide some support.
Dividend increase is modest but can support income-focused demand and signal steady cash generation.
The dividend hike signals stronger cash flow and may attract income-focused investors.
Likely mild positive sentiment from insider buying, but the transaction size is small and indirect, so near-term price impact is limited.
Buyback creates modest buying pressure.
AlphAI scores every news story that mentions UTMD with an AI model for sentiment and relevance, and aggregates insider trades from UTAH MEDICAL PRODUCTS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Utah Medical Products reported 3Q 2026 revenue of $8.62M, down 12.1% YoY, and net income of $2.79M, up 5.9% YoY. The decline was attributed to lower sales to former major customers and declining Filshie sales, while earnings were supported by lower expenses and a lower tax rate. Management expects full-year 2026 sales to decline 7%-8% from 2025, with EPS close to $3.60 per share.
UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Utah Medical Products, Inc. Increases Quarterly Dividend Contact: Brian Koopman November 3, 2026 (801) 566-1200 Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors has approved a quarterly cash dividend of thirty-on
Utah Medical Products (UTMD) raised its quarterly dividend by 1.6% to $0.315 per share. The payment is scheduled for January 5, 2027, to shareholders of record on December 17, 2026. The company develops specialty medical devices for women and babies.
CORNWELL KEVIN L (Chairman, CEO) purchased 1,000 indirectly-held shares of UTAH MEDICAL PRODUCTS INC (UTMD) at $66.75 on 2026-10-29.
Utah Medical Products (UTMD) repurchased 327,740 shares for $24.6M. The company develops and markets medical devices, focusing on women and infant healthcare.
Utah Medical Products (UTMD) bought back 322,215 shares at $75.36 per share, part of a plan to purchase up to 650,000 shares. The company makes medical devices for women and babies, sold globally. UTMD is listed on NASDAQ.
Utah Medical Products reported Q3 2026 revenue of $8.621M, down 12.1% YoY, with net income up 5.9% to $2.787M. Nine-month revenue fell 12.2% to $25.873M, and net income declined 7.4% to $8.077M. The company attributed the revenue decline to lost customers and weaker sales in key products. Management projected a full-year 2026 sales decline of about 7%.
UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 Contact: Brian Koopman (801) 566-1200 October 22, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports third quarter (3Q) and first nine months (9M) of calend
Utah Medical Products (UTMD) offers to buy up to 650,000 shares at $75 each, a 17% premium over the 12-month average. The tender offer, approved by the board, aims to provide liquidity. UTMD's H1 2026 sales and profits declined 12% and 13% YoY, with recent EBITDA at $15.7M. CEO Cornwell believes shares are undervalued, citing industry multiples. The offer expires Oct 7 unless extended.
Utah Medical Products (UTMD) announced a self-tender offer to repurchase up to 650,000 shares, or 20% of its outstanding shares, at $75.00 per share. This price is 17% higher than the 12-month average and 21% higher than the 2-year average. The offer, starting September 22, is not conditioned on a minimum number of shares. The company's board approved the offer but did not recommend it to stockholders.
